Candriam S.C.A. boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 159.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,430 shares of the medical research company’s stock after buying an additional 53,149 shares during the period. Candriam S.C.A.’s holdings in Charles River Laboratories International were worth $14,909,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of CRL. Sequoia Financial Advisors LLC boosted its holdings in Charles River Laboratories International by 8.9% in the 1st quarter. Sequoia Financial Advisors LLC now owns 3,493 shares of the medical research company’s stock valued at $603,000 after purchasing an additional 285 shares during the period. Hsbc Holdings PLC grew its position in Charles River Laboratories International by 12.2% in the 1st quarter. Hsbc Holdings PLC now owns 69,682 shares of the medical research company’s stock worth $11,977,000 after purchasing an additional 7,598 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Charles River Laboratories International by 9.3% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,848 shares of the medical research company’s stock worth $491,000 after purchasing an additional 242 shares during the period. Praxis Investment Management Inc. increased its holdings in shares of Charles River Laboratories International by 49.8% during the 1st quarter. Praxis Investment Management Inc. now owns 1,916 shares of the medical research company’s stock worth $331,000 after purchasing an additional 637 shares during the period. Finally, HB Wealth Management LLC raised its position in shares of Charles River Laboratories International by 5.9% during the first quarter. HB Wealth Management LLC now owns 2,676 shares of the medical research company’s stock valued at $462,000 after buying an additional 148 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.
Charles River Laboratories International Price Performance
Charles River Laboratories International stock traded up $0.19 during mid-day trading on Friday, hitting $233.79. 873,205 shares of the company were exchanged, compared to its average volume of 808,932. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $237.86. The company has a market capitalization of $11.26 billion, a PE ratio of -62.18, a price-to-earnings-growth ratio of 2.66 and a beta of 1.40. The business has a fifty day moving average of $187.76 and a 200 day moving average of $185.87. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90.
Analysts Set New Price Targets
Several research firms recently weighed in on CRL. Morgan Stanley increased their target price on shares of Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank Of Canada assumed coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. Robert W. Baird set a $213.00 price objective on Charles River Laboratories International in a research report on Friday, May 8th. CLSA raised Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their target price for the stock from $167.00 to $219.00 in a research report on Friday, May 29th. Finally, Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. Twelve equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $218.38.
Get Our Latest Stock Analysis on Charles River Laboratories International
Insider Activity at Charles River Laboratories International
In other news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. The trade was a 70.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by insiders.
Charles River Laboratories International Profile
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
- Why “Big Short” Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
